Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity

Pharmacogenomics

Volumn 16, Issue 4, 2015, Pages 323-332

  Lanvers Kaminsky, Claudia ^a   Sprowl, Jason A ^b   Malath, Ingrid ^a   Deuster, Dirk ^a   Eveslage, Maria ^c   Schlatter, Eberhard ^a   Mathijssen, Ron H J ^d   Boos, Joachim ^a   Jürgens, Heribert ^a   Am Zehnhoff Dinnesen, Antionette G ^a,b   Sparreboom, Alex ^b,d   Ciarimboli, Giuliano ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

cisplatin; ototoxicity; polymorphism; SLC22A2; SLC31A1

Indexed keywords

CISPLATIN; GUANINE; ORGANIC CATION TRANSPORTER 2; THYMINE; CATION TRANSPORT PROTEIN; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN; SLC31A1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG TRANSPORT; EAR PROTECTION; FEMALE; FISHER EXACT TEST; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; OTOTOXICITY; PHARMACOGENOMICS; PROTEIN LOCALIZATION; ADVERSE DRUG REACTION; GENETIC ASSOCIATION STUDY; GENETICS; HAPLOTYPE; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CATION TRANSPORT PROTEINS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; MALE; NEOPLASMS; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84926032229     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.182     Document Type: Article

References (44)

1. Brock PR, Knight KR, Freyer DR et al. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 30, 2408-2417 (2012).
2. Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst. Rev. 10, CD008944 (2013).
3. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 23, 8588-8596 (2005).
4. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J. Clin. Oncol. 25, 1190-1195 (2007).
5. Bokemeyer C, Berger CC, Hartmann JT et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77, 1355-1362 (1998).
6. Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M, Medina-Sansón A. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr. Hematol. Oncol. 24, 403-408 (2007).
7. Fisher MJ, Lange BJ, Needle MN et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr. Blood Cancer. 43, 780-784 (2004).
8. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: A practical grading system. Med. Pediatr. Oncol. 19, 295-300 (1991).
9. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J. Clin. Oncol. 28, 1788-1795 (2010).
10. Khan AB, D'Souza BJ, Wharam MD et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat. Rep. 66, 2013-2020 (1982).
11. Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy. HNO 55, 299-306 (2007).
12. Lafay-Cousin L1, Purdy E, Huang A et al. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr. Blood Cancer. 60, 287-292 (2013).
13. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr. Blood Cancer 59, 144-148 (2012).
14. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40, 2445-2451 (2004).
15. Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Ototoxicity in children treated for osteosarcoma. Pediatr. Blood Cancer 52, 387-391 (2009).
16. Landier W, Knight K, Wong FL et al. Ototoxicity in children with high-Risk neuroblastoma: prevalence, risk factors, and concordance of grading scales-A report from the Children's Oncology Group. J. Clin. Oncol. 32, 527-534 (2014).
17. Zuur CL, Simis YJ, Lansdaal PE et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: A multivariate analysis. Int. J. Radiat. Oncol. Biol. Phys. 68, 1320-1325 (2007).
18. Skinner R, Pearson AD, Amineddine HA, Mathias DB, Craft AW. Ototoxicity of cisplatinum in children and adolescents. Br. J. Cancer. 61, 927-931 (1990).
19. Ross CJ, Katzov-Eckert H, Dubé MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
20. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94, 243-251 (2013).
21. Peters U, Preisler-Adams S, Hebeisen A et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 11, 639-643 (2000).
22. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708-714 (2007).
23. Caronia D, Patiño-García A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 9, 347-353 (2009).
24. Riedemann L, Lanvers C, Deuster D et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8, 23-28 (2008).
25. Choeyprasert W, Sawangpanich R, Lertsukprasert K et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J. Pediatr. Hematol. Oncol. 35, e138-e143 (2013).
26. Xu X, Ren H, Zhou B et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 77, 438-442 (2012).
27. Ivy KD, Kaplan JH. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinumdrug entry into human cells. Mol. Pharmacol. 83, 1237-1246 (2013).
28. Katano K, Kondo A, Safaei R et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 62, 6559-6565 (2002).
29. More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 30, 9500-9509 (2010).
30. Ciarimboli G, Deuster D, Knief A et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169-1180 (2010).
31. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter
32. (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
33. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 14, 3875-3880 (2008).
34. US FDA Drug Interactions & Labeling. www.fda.gov
35. Loos WJ, de Jongh FE, Sparreboom A et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J. Clin. Oncol. 24, 1499-1506 (2006).
36. Haploview. www.broadinstitute.org/scientificcommunity/science/ programs/medical-and-population-genetics
37. International HapMap Project. www.hapmap.org
38. Leabman MK, Huang CC, Kawamoto M et al. Pharmacogenetics of Membrane Transporters Investigators. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12, 395-405 (2002).
39. de Jongh FE, van Veen RN, Veltman SJ et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 88, 1199-1206 (2003).
40. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG et al. Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr. Blood Cancer 47, 183-193 (2006).
41. Zolk O, Solbach TF, König J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab. Dispos. 37, 1312-1318 (2009).
42. Kang HJ, Song IS, Shin HJ et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos. 35, 667-675 (2007).
43. Zhang J, Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatininduced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol. 50, 2289-2293 (2012).
44. Yang JJ, Lim JY, Huang J et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94, 252-259 (2013).